News

QLT091001 works as a replacement for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, and is used to treat the inherited retinal degenerative diseases Leber Congenital

The cPMP replacement therapy is designed to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare genetic disorder characterized severe brain damage and rapid death in

Dyadic is focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bio-energy, industrial enzyme and biopharmaceutical industries. The patent is

Pharmacies can now scale from entry level, tabletop unit dose or fluid dose packager to fully automated unit dose packager and multi-dose packager. TCGRx said the ATP Series

Fourth quarter 2010 R&D expenses decreased to $23.6m from $31.6m in last year, driven by lower development costs associated with the peramivir and forodesine clinical programs. Total revenues

The HQM Reporting Module is a proprietary, clinical data repository which does the automated registry reporting of clinical outcomes, and quality measure data for pay-for-performance (P4P) programs. The

Anacor will receive a $7m upfront payment from Medicis and will be primarily responsible for discovering and conducting early development of product candidates which utilize Anacor’s proprietary boron

Initially, the PKD Foundation will help Intellikine to evaluate the drug candidates using pre-clinical models of the disease. PKD Foundation chief scientific officer Jill Panetta said Intellikine is

The trial aims to assess the safety, tolerability and pharmacokinetics in healthy volunteers. TMC649128, a nucleoside NS5B polymerase inhibitor with an exciting pre-clinical profile, is indicated for the